Trevena
Trevena develops innovative medicines for central nervous system disorders and has one FDA-approved product, OLINVYK (oliceridine) injection. The company is based in Chesterbrook, PA, and has a pipeline that includes investigational drugs TRV045, TRV250, and TRV734.
Innovative Medicines for Central Nervous System Disorders
Trevena focuses on developing innovative medicines specifically designed for patients with central nervous system disorders. Their efforts center on creating solutions that address significant medical needs in this field. The company's expertise in this area is reflected in their dedication to advancing novel therapeutic options.
FDA-Approved Product: OLINVYK
Trevena has secured FDA approval for OLINVYK (oliceridine) injection, which is available in the United States. OLINVYK is a prescription medicine used to manage acute pain severe enough to require an intravenous opioid analgesic. The approval of OLINVYK marks a significant milestone in Trevena's mission to offer innovative pain management solutions.
Pipeline of Investigational Drug Candidates
Trevena's pipeline consists of several promising investigational drug candidates aimed at treating a range of conditions. TRV045 is in development for diabetic neuropathic pain and epilepsy. TRV250 is targeted for the acute treatment of migraine, while TRV734 is focused on the maintenance treatment of opioid use disorder. These candidates highlight Trevena’s commitment to addressing various unmet medical needs.
Private Placement Fundraising
In December 2023, Trevena successfully raised $4 million through a private placement and warrant exercise. This fundraising effort provides crucial financial resources to support the continued development of their pipeline and other operational needs. The company's ability to secure funding is indicative of investor confidence in their strategic vision and potential advancements.
Location
Trevena is headquartered in Chesterbrook, PA. This location serves as the central hub for their research, development, and administrative activities. Being based in Chesterbrook allows the company to leverage regional resources and talent to advance their mission of developing groundbreaking therapies for central nervous system disorders.